Celularity Incis A Biotechnology Company Based In Florham Parknew Jerseyspecializing In Regenerative And Cellular Medicinefounded In 2017 As A Spin Off From Celgene Corporationthe Company Focuses On Developing Therapies From Postpartum Placental Cells To Treat Aging Related Diseasescancerand Immune Disorders Celularity Offers Allogeneic Cell Therapiesincluding Cryopreserved Placental Derived Cell Therapies Like Mesenchymal Like Adherent Stromal Cellscar T Cellsand Natural Killer Cellsthe Company Is Advancing Several Key Pipeline Candidatessuch As Cynca 1 For Solid Tumors And Cynca 2 For Cancer Immunotherapyin 2023Celularity Invested Significantly In Research And Developmentwith Active Clinical Trials In Oncology And Regenerative Medicinethe Company Collaborates With Notable Partnersincluding Memorial Sloan Kettering Cancer Centerand Has Raised Substantial Funding To Support Its Mission Of Delivering Scalablecost Effective Therapies
